{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.4","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"87.2","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Ovulation was defined as mid-luteal serum progesterone level of \\>= 5 ng/mL or clinical pregnancy. Clinical pregnancy was defined as the presence of at least a fetal sac on transvaginal ultrasound (TVUS).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol (starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days was done if no ovarian response was observed) for maximum of 28 days received a single dose of 250 microgram (mcg) MSJ-0011 subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \\>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).","id":"OG000","title":"MSJ-0011"},{"description":"Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol (starting dose of follitropin alfa as 75 IIU subcutaneously per day ,increments by 37.5 IU every 7 days was done if no ovarian response was observed) for maximum of 28 days received a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of \\>=18 mm; not more than 3 follicles each with a mean diameter of \\>=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.","id":"OG001","title":"u-hCG"}],"paramType":"NUMBER","populationDescription":"The modified intent to treat (Mod ITT) population was defined as all subjects randomized to IMP (MSJ-0011 or u-hCG) and who completed the primary efficacy assessment.","reportingStatus":"POSTED","timeFrame":"Mid-luteal phase progesterone assessed (Day 5 to 10) or clinical pregnancy (Day 35 to 42) post hCG treatment","title":"Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy","type":"PRIMARY","unitOfMeasure":"percentage of subjects"}